ARTICLE
22 March 2013

Gilead Leave To Appeal To Supreme Court Of Canada Dismissed Re: FCA Decision Not To List Patent On Register Due To Lack Of Product Specificity Under PM(NOC) Regulations

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
In Gilead Sciences Canada Inc. v. Canada, 2012 FCA 254, the Federal Court of Appeal dismissed Gilead's appeal of the Minister's decision not to list Canadian Patent No. 2,512,475 on the patent register.
Canada Intellectual Property

In Gilead Sciences Canada Inc. v. Canada (Minister of Health), 2012 FCA 254, the Federal Court of Appeal (FCA) dismissed Gilead's appeal of the Minister's decision not to list Canadian Patent No. 2,512,475 (the '475 Patent) on the patent register. In the Minister's view, the '475 Patent failed to meet the requirements of the Patented Medicine (Notice of Compliance) Regulations (PM(NOC)) because it did not specifically claim all the medicinal ingredients in the New Drug Submission (NDS).

The '475 Patent specifically claimed two of three medicinal ingredients, but claimed the third as an unnamed agent selected from a class, rather than the actual ingredient. In his final decision, the Minister wrote, "a patent containing claims for a formulation cannot 'match' the approved formulation [in the NDS or NOC] unless both formulations explicitly contain all of the same medicinal ingredients." Classes of ingredients therefore failed to meet the "matching requirement" due to a lack of product specificity, and the '475 Patent could not be listed. This decision was upheld by Justice Mosley of the Federal Court under paragraph 4(2)(b) of the PM(NOC).

The FCA held that Justice Mosley should have construed the '475 Patent claims and then interpreted paragraphs 4(2)(a) and (b) of the PM(NOC) to determine under what paragraph the claims best fit. The FCA concluded that paragraph 4(2)(a) was the most appropriate, as the claims were for a new combination of chemically-stable medicinal ingredients. Citing Purdue Pharma v. Canada (Attorney General), 2011 FCA 132, the Court noted that without specific and exact matching between patent claims and an approved NOC, a patent will not be eligible for listing on the register due to a lack of product specificity as required by paragraph 4(2)(a) of the PM(NOC). The Court dismissed Gilead's appeal. Gilead's leave to appeal to the Supreme Court of Canada has been dismissed without costs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More